Blog
RSS FeedPosted by Michael Wonder on 23 Nov 2022
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after one systemic treatment
23 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 22 Nov 2022
NICE recommends Sobi’s Doptelet to treat thrombocytopenia
18 November 2022 - Primary ITP is a rare autoimmune condition characterised by high platelet destruction ...
Posted by Michael Wonder on 17 Nov 2022
NICE recommends 3 treatments for COVID-19 in draft guidance
16 November 2022 - Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation. ...
Posted by Michael Wonder on 17 Nov 2022
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
16 November 2022 - Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer. ...
Posted by Michael Wonder on 16 Nov 2022
Ruxolitinib phosphate for the treatment of patients with acute graft versus host disease that is refractory to the use of corticosteroids
16 November 2022 - NICE is unable to make a recommendation about the use in the NHS of ruxolitinib phosphate for ...
Posted by Michael Wonder on 08 Nov 2022
NICE final draft guidance adds further treatment option for triple negative breast cancer
8 November 2022 - NICE has today published final draft guidance which recommends pembrolizumab as an option for people with ...
Posted by Michael Wonder on 06 Nov 2022
Bulevirtide acetate for the treatment of patients with chronic hepatitis D
4 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Nov 2022
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis
2 November 2022 - NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal ...
Posted by Michael Wonder on 19 Oct 2022
Fostamatinib disodium hexahydrate for the treatment of patients with refractory chronic immune thrombocytopenia
19 October 2022 - NICE has published evidence-based recommendations on the use of fostamatinib disodium hexahydrate for the treatment of ...
Posted by Michael Wonder on 19 Oct 2022
Zanubrutinib for the treatment of patients with Waldenström’s macroglobulinaemia
19 October 2022 - NICE has published evidence-based recommendations on the use of zanubrutinib for the treatment of adults with ...
Posted by Michael Wonder on 19 Oct 2022
Oestradiol hemifumarate with norethisterone acetate and relugolix for the treatment of moderate to severe symptoms of uterine fibroids
19 October 2022 - NICE has published evidence based recommendations on the use of oestradiol hemifumarate with norethisterone acetate and ...
Posted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults ...
Posted by Michael Wonder on 12 Oct 2022
SQ HDM SLIT for the treatment of patients with allergic rhinitis and allergic asthma caused by house dust mites
12 October 2022 - NICE is unable to make a recommendation on the use of SQ HDM SLIT (Acarizax) for the ...
Posted by Michael Wonder on 05 Oct 2022
Ozanimod hydrochloride for treating moderate to severe active ulcerative colitis
5 October 2022 - NICE has published evidence based recommendations on the use of ozanimod hydrochloride for the treatment of ...
Posted by Michael Wonder on 05 Oct 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
5 October 2022 - NICE has published evidence based recommendations on the use of azacitidine for the maintenance treatment of ...